These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8570443)

  • 1. Cost comparison of beta 2-agonist bronchodilators used in the treatment of asthma.
    Nightingale CH
    Pharmacotherapy; 1995; 15(5):677-81. PubMed ID: 8570443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The technology of metered-dose inhalers and treatment costs in asthma: a retrospective study of breath actuation versus traditional press-and-breathe inhalers.
    Langley PC
    Clin Ther; 1999 Jan; 21(1):236-53. PubMed ID: 10090438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma.
    Rutten-van Mölken MP; van Doorslaer EK; Till MD
    Pharmacoeconomics; 1998 Dec; 14(6):671-84. PubMed ID: 10346418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salmeterol. An appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma.
    Peters DH; Faulds D
    Pharmacoeconomics; 1995 Jun; 7(6):562-74. PubMed ID: 10155341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma.
    Everden P; Lloyd A; Hutchinson J; Plumb J
    Respir Med; 2002 Apr; 96(4):250-8. PubMed ID: 12000004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
    Markham A; Jarvis B
    Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database.
    Price DB; Cargill K; Wolfe S; Darby H
    Respir Med; 1998 Nov; 92(11):1302-4. PubMed ID: 9926144
    [No Abstract]   [Full Text] [Related]  

  • 8. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
    D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
    JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.
    Markham A; Adkins JC
    Pharmacoeconomics; 2000 Dec; 18(6):591-608. PubMed ID: 11227397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salmeterol: a long-acting beta 2-agonist for asthma.
    Nurse Pract; 1994 Jul; 19(7):9-10. PubMed ID: 7936460
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
    Doull I; Price D; Thomas M; Hawkins N; Stamuli E; Tabberer M; Gosden T; Rudge H
    Curr Med Res Opin; 2007 May; 23(5):1147-59. PubMed ID: 17519082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pressurised metered-dose inhalers (MDIs) versus dry powder inhalers devices (DPIs) to rapid-acting inhaled b2-agonists for asthma in children.
    Negro Alvarez JM; Miralles López JC; Félix Toledo R; Pagán Alemán JA; García Sellés FJ; López Sánchez JD; Hernández García J
    Allergol Immunopathol (Madr); 2002; 30(4):245-9. PubMed ID: 12199971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs.
    Stempel DA; O'Donnell JC; Meyer JW
    J Allergy Clin Immunol; 2002 Mar; 109(3):433-9. PubMed ID: 11897987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma.
    Miller E; Sears MR; McIvor A; Liovas A
    Can Respir J; 2007; 14(5):269-75. PubMed ID: 17703241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluations.
    Anthonisen NR
    Can Respir J; 2007; 14(5):264-6. PubMed ID: 17874484
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2003; 21(13):951-89. PubMed ID: 12959627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
    Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
    Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serevent in the treatment of moderate bronchial asthma].
    Panghea P; Voicu G; Filip G; Arghir O; Floca L; Acasandri E; Mihai D
    Pneumoftiziologia; 1996; 45(3-4):145-8. PubMed ID: 9221040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long acting beta-agonists versus theophylline for maintenance treatment of asthma.
    Wilson AJ; Gibson PG; Coughlan J
    Cochrane Database Syst Rev; 2000; (2):CD001281. PubMed ID: 10796631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.